ELL Antibody [B15J21] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Lane 1: 293T, Lane 2: 3T3, Lane 3: C2C12, Lane 4: H-4-II-E

Usage Information

Dilution
WB1:1000 IP1:100 IF1:1600 CHIP1:100

Application
WB, IP, IF, ChIP

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
70 kDa

Datasheet & SDS

Biological Description

Specificity
ELL Antibody [B15J21] detects endogenous levels of total ELL protein.

Clone
B15J21

Synonym(s)
RNA polymerase II elongation factor ELL; ELL

Background
Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

Background

Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

References
https://pubmed.ncbi.nlm.nih.gov/22252557/ https://pubmed.ncbi.nlm.nih.gov/9268387/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%